Skip to Content Facebook Feature Image

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026

Business

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026
Business

Business

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026

2026-09-24 21:24 Last Updated At:23:35

HONG KONG, Sept. 24, 2026 /PRNewswire/ -- Speaking for the first time at the World Cancer Congress in Hong Kong this week, Médecins Sans Frontières/Doctors Without Borders (MSF), an international medical humanitarian organisation, will share its experiences from its cancer programmes in Mali and Malawi, highlighting that cancer care is possible in resource-limited settings, but urgent action is needed to break barriers to accessing prevention, timely diagnosis and adequate treatment.

The burden of cancer is already a growing public health threat in many countries where MSF works – and women are disproportionately affected. About 80 per cent of deaths from breast and cervical cancer worldwide happen in low- and middle-income countries. By 2050, global health experts estimate the number of cancer cases in such countries will rise by 150 per cent.

"Ten years ago during the Syrian crisis, we were ill-equipped to respond to the health needs of displaced people whose treatment for non-communicable diseases, including cancer, had been abruptly interrupted by the conflict," says Dr Claire Rieux, MSF's medical director. "Today, our teams provide cancer care, from screening to treatment and palliative care, in several countries. We partner with ministries of health, inspiring practitioners, community networks and experts in the fight against cancer. We are eager to keep learning and contribute to advance greater equity in this field."

Cancer Care in Mali and Malawi

Over the last five years, MSF has developed and supported cancer-related activities in countries including Malawi, Mali, Papua New Guinea, Ukraine, Kyrgyzstan and Eswatini.

In Mali, more than 2,300 women received medical care for breast or cervical cancer between 2021 and 2025 through the programme run by MSF and its partners in Bamako. A retrospective study to assess treatment results of women cared for by MSF and the Malian Ministry of Health between 2019 and 2022 shows tangible progress – despite unreliable access to radiotherapy, security constraints and the many obstacles that stand in the way of care for people living with cancer. Only one quarter of the patients were diagnosed at an early stage of the disease, but the proportion kept improving over time – for instance, for women with cervical cancer, it doubled between 2019 (14 per cent) and 2022 (28 per cent). The retrospective study also found global survival rates for women with breast cancer that stood at 91 per cent a year after the diagnosis and 72 per cent after three years. These rates are promising but should be interpreted with caution given the high proportion of patients whose survival status was unknown in the study (30 per cent of "lost to follow up" patients).

In Malawi, our programme in Blantyre helps to tackle the world's second-highest cervical cancer mortality rate by facilitating access to palliative care and treatment, including chemotherapy, surgery and radiotherapy, and to prevention tools, including vaccination against human papillomavirus (HPV), early screening and treatment of precancerous lesions. In Blantyre district, the coverage of cervical cancer screening increased from 40 per cent in 2019 to close to 60 per cent last year.

MSF also joined the PAVE study, an international research project designed to trial a new, low-cost strategy for screening and treating pre-cancerous cervical lesions in resource-limited settings. The strategy, which combines HPV genotyping and artificial intelligence-automated visual evaluation to detect precancerous lesions, was found particularly effective to achieve better detection and to better identify the most at-risk women in need of urgent treatment. Yet improved screening yields limited results if the next stages of diagnosis and care remain unavailable, unaffordable or oversubscribed.

Calling for Greater Access to Cancer Care

"Too often, people with cancer are denied access to treatment and care not because effective tools do not exist, but because they are priced out of reach, unavailable when they are needed, or not suitable for resource-limited settings and countries. It's time for countries and funders to show a strong political will to close this gap by investing in cancer care and ensuring that lifesaving diagnostics and treatments are affordable, adaptable and available for people in low-resource and humanitarian settings," says Dr Zarak Jan, MSF Access advocacy advisor.

MSF will speak on Friday 25 September in two sessions: Cancer care in humanitarian crises: from neglect to action and Making cancer care possible: sharing experiences from MSF in humanitarian and low-resource settings. Through this unique opportunity, MSF aims to advocate for greater access to comprehensive care for people with cancer, exchange ideas with the global cancer community and learn about the latest innovations and successful initiatives in cancer control.

About MSF

MSF is an independent international medical humanitarian organisation. We are committed to providing emergency medical assistance to people affected by armed conflict, epidemics and natural disasters, and those who have been excluded from the health care system. MSF will only provide assistance based on people's needs, regardless of race, religion, gender or politics.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026

MSF Shares Experience in Delivering Cancer Care to Women in Humanitarian Crises at World Cancer Congress 2026

  • The Distribution agreement covers the United States and Canada, with sales through the partnership to begin in the U.S.
  • WIM S is available to U.S. consumers online through Ottobock's direct-to-consumer platform and WIRobotics USA's online store.
  • U.S. consumers will be able to try WIM S at select orthotic and prosthetic clinics.

SEOUL, South Korea, Nov. 17, 2026 /PRNewswire/ -- WIRobotics, a global robotics company led by Co-CEOs Younbaek Lee and Yongjae Kim, announced that its U.S. subsidiary, WIRobotics USA Inc., signed a distribution and sales agreement with Otto Bock HealthCare LP on October 15. Under the agreement, WIRobotics USA will supply WIM S, the company's wearable mobility robot, and Ottobock will serve as a distribution partner in the United States and Canada.

The partnership will begin in the United States, where consumers will be able to purchase WIM S online through Ottobock's dedicated direct-to-consumer online platform and WIRobotics USA's online store, and try the robot initially at select orthotic and prosthetic (O&P) clinics. Based on customer feedback, the companies will consider offering hands-on experiences at more U.S. locations and extending sales through the partnership to Canada. 

The partnership brings together WIRobotics' wearable robotics technology and Ottobock's more than 100 years of experience in human mobility. Founded in Germany in 1919, Ottobock has established distribution, clinical care and service networks in the United States and Canada. The companies plan to collaborate on market development, brand building, product training and after-sales service, with WIRobotics USA supporting training and service operations locally.

The agreement marks a major step in WIRobotics' global expansion. Now in its third year of commercialization, WIM has surpassed 4,000 units in cumulative sales, and the company has expanded sales beyond South Korea to markets including Europe, China and Japan. WIRobotics has been accelerating its international business, with the United States and Canada as key strategic markets. To support this growth, the company established WIRobotics USA Inc. under General Manager Jacob Kim to build local operations in North America.

The companies also see significant opportunities to extend their collaboration to WIM Medi, which WIRobotics is developing for medical use. They view WIM Medi as a natural next step for the partnership, with entry into U.S. and Canadian medical and rehabilitation channels to follow applicable regulatory authorization and a separate agreement.

"Our goal is to make wearable mobility technology easier for people to experience and integrate into everyday life," said Younbaek Lee, co-CEO of WIRobotics. "Working with Ottobock gives us an opportunity to introduce WIM S to more people across North America. We will expand our engagement with customers in the region and strengthen WIM's global business foundation."

"At Ottobock, we are committed to helping people maintain mobility and independence through innovative solutions that support an active lifestyle," said Scott Schneider, Head of Government/Medical Affairs & Future Development at Ottobock. "WIRobotics is an exceptional company whose technology closely aligns with that vision. Through this partnership, we look forward to introducing WIM S to consumers across North America, beginning with a focused U.S. launch, while exploring new ways for people to experience wearable mobility technology firsthand."

About WIRobotics
WIRobotics is a global robotics company that develops wearable mobility robots designed to help people move more freely in everyday life. Its WIM series is sold in South Korea and international markets.  Through the development of its ALLEX humanoid robot, the company is also expanding into humanoid robotics and Physical AI. In May 2026, the company raised KRW 95 billion (approximately USD 68 million) in Series B funding to accelerate its global expansion and the commercialization of its robotics technologies. Headquartered in South Korea, the company operates in North America through WIRobotics USA Inc. For more information, visit https://usa.wirobotics.com

About Ottobock
Ottobock, a listed global MedTech champion, combines over 100 years of tradition with outstanding innovative strength in the fields of prosthetics, neuro-orthotics and exoskeletons. Ottobock develops innovative fitting solutions for people with limited mobility and is driving the digitalization of the industry. Founded in Berlin in 1919, the company has business activities in 45 countries with nearly 9,300 employees (FTEs) worldwide and operates the largest international patient care network with more than 430 patient care clinics. Ottobock is shaping the future of human bionics with a strong R&D ratio in the products and components business and over 2,600 patents and patent applications. Ottobock's mission of improving freedom of movement, quality of life and independence is deeply rooted in the company's DNA, as is its social commitment: Ottobock has been a partner and supporter of the Paralympics since 1988.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

WIRobotics and Ottobock Join Forces to Expand Access to Wearable Robots Across North America

WIRobotics and Ottobock Join Forces to Expand Access to Wearable Robots Across North America

Recommended Articles